INTRODUCTION
In clinical settings anticonvulsants are sometimes utilized to augment treatment among individuals with schizophrenia (Citrome et al., 2000) , and there are reports suggesting that augmentation anticonvulsant therapy may improve schizophrenia symptoms (Wassef et al., 2000; Casey et al., 2003; .
The issue of older adults with schizophrenia has gained attention due to the growing proportion of elderly world-wide (CDC, 2004; Jeste et al., 1999) . In geropsychiatric settings up to 65% of older adults with schizophrenia/schizoaffective disorder receive anticonvulsant medication (Sajatovic et al., 2004) . Although utilization of anticonvulsants, valproate semisodium in particular, is routinely seen in clinical settings, how this augmentation specifically benefits older adults with schizophrenia is not clear. This is a first report of a prospective trial of adjunctive extended-release valproate semisodium (divalproex) therapy focused on older adults with schizophrenia. We hypothesized that adjunctive extended-release valproate semisodium would be well-tolerated and associated with improvements in symptoms, level of functioning, and general health status.
METHODS
This was extended-release open-label, 12-week prospective trial of add-on valproate semisodium therapy in 20 older adults with schizophrenia as confirmed by the Mini International Neuropsychiatric Interview (MINI; Sheehan et al., 1998) . The study was conducted at an academic psychiatry clinic in the mid-western United States. Participants were recruited in response to self-referrals from posted advertisements and by referrals from mental health practitioners at the academic clinic and a nearby community mental health clinic. Individuals were considered sub-optimally responsive to current antipsychotic medications if, based upon either self-report or report of care providers, they had remaining symptoms of schizophrenia that either affected their ability to meet daily needs or their ability to interact with others. All patients provided written informed consent, and the study was approved by the local institutional review board (IRB). Eligible subjects were receiving antipsychotic medications for the treatment of schizophrenia. Individuals with acute medical illness, including those positive for Hepatitis C, and those with active substance abuse were excluded. Individuals were only considered for participation if they had not received a valproate trial in the past.
Enrolled individuals received adjunctive, openlabel valproate semisodium, initially started as valproate semisodium delayed-release 250 mg at bedtime for two weeks, then changed to valproate semisodium extended-release 500 mg at bedtime. Medication was administered on an outpatient/ambulatory basis, and adjusted as tolerated to target serum levels of 50-100 mg/mL. In cases where sedation or other side effects occurred, dosage was reduced. Valproate semisodium was prescribed in a single dose at bedtime.
The primary outcome measure was change from baseline on a schizophrenia psychopathology assessment, the Positive and Negative Syndrome Scale (PANSS; Kay et al., 1987) . Secondary outcomes included change from baseline on a measure of depression [the Geriatric Depression Scale (GDS: Yesavage et al., 1982) ], overall change in functioning [Global Assessment Scale (GAS; Guy, 1976) Folstein et al., 1975) ]. Extrapyramidal symptoms were evaluated with the Abnormal Involuntary Movement Scale (AIMS; Guy, 1976) , the Barnes Akathisia Scale (BAS; Barnes, 1989) , and the Simpson Angus Neurological Rating Scale (SAS; Simpson and Angus, 1970) .
All rating scale measures were conducted at baseline, and at weeks 2,4,8 and 12 (end of study). All patients had baseline assessment of basic serum chemistry, metabolic profile, complete blood count (CBC) with differential, vital signs, weight and electrocardiogram. Vital signs and weight were assessed at each study visit, and laboratory testing was repeated again at end of study. Serum total valproate levels were obtained by week 4, and at weeks 8 and 12.
Efficacy and safety results were calculated using descriptive statistics. Scores for each rating scale over time were evaluated using paired t-tests comparing baseline and last available assessment of each measure. The intent-to-treat (ITT) population was defined as individuals who received at least one dose of valproate semisodium. Table 1 illustrates sample baseline clinical characteristics. Mean age was 61.5 years, SD AE 9.4, range 49.8-79.2 years. This was a chronically mentally ill population, with mean age of 31.2 AE SD 18.1 years at illness onset, and mean duration of illness of 29.2 AE 13.3 years. The majority of patients had moderate baseline symptoms of schizophrenia with a mean PANSS score of 72.65 AE 17.17, mean PANSS negative sub-scale 18.20 AE 6.30, and mean PANSS positive subscale 17.90 AE 3.51. This was a non-demented population with a mean MMSE score of 27.50 AE 1.73, range 24-30.
RESULTS

Clinical characteristics of the sample
Concomitant antipsychotic medications included risperidone (n ¼ 6, 33%), olanzapine (n ¼ 4, 20%), aripiprazole (n ¼ 4, 20%), quetiapine (n ¼ 3, 15%), and clozapine (n ¼ 1, 5%). One individual was on both olanzapine and long-acting injectable risperidone, and one individual was on both olanzapine and aripiprazole. There were four individuals on conventional antipsychotics (haloperidol n ¼ 3, thiothixene n ¼ 1), including two on long-acting injectable haloperidol. During the study there were five individuals who had reductions in their antipsychotic medication dosing (four individuals to reduce extrapyramidal symptoms (haloperidol n ¼ 2, thiothixene n ¼ 1, risperidone n ¼ 1), and one individual on olanzapine to attempt to reduce propensity for weight gain). Baseline chlorpromazine (CPZ) equivalents (Fuller and Sajatovic, 2007) for individuals that were on oral antipsychotic medications was 375 CPZ equivalents/day (SD AE 268.3, range 100-1,250 CPZ equivalents/day), while endpoint CPZ equivalents was 303 CPZ equivalents/day (SD AE 288.5), a difference that was not statistically significant ( p > 0.05).
Comorbid medical conditions were common, and included hypertension (n ¼ 9, 45%), diabetes (n ¼ 8, 40%), hyperlipidemia/cholesterolemia (n ¼ 6, 30%), coronary artery disease (n ¼ 5, 20%), chronic renal insufficiency (n ¼ 3, 15%), arthritis (n ¼ 3, 15%), morbid obesity (n ¼ 3, 15%) and one individual each (5%) with chronic pain, chronic osteomyelitis, GERD, Parkinson's disease, hypothyroidism, sarcoidosis and seizure disorder. 
DISCUSSION
This open-label, pilot study suggests that adjunctive extended-release valproate semisodium is relatively well tolerated and may be associated with improvements in psychopathology among older adults with schizophrenia. While 25% of individuals in the study presented here dropped out prematurely, none did so because of adverse events related to study medication. Recent large-scale treatment trials involving mixed age patients with schizophrenia (Lieberman et al., 2005; Jones et al., 2006 ) demonstrate early medication discontinuation or medication switching rates in the order of 46-74%. Low persistence with medication treatment appears to be a pervasive problem among populations with schizophrenia that complicates interpretation of studies of schizophrenia treatments.
Casey and colleagues (2003) conducted a double blind, randomized study of valproate semisodium with an antipsychotic agent for mixed age individuals with schizophrenia. Patients were treated with either olanzapine or risperidone monotherapy, valproate semisodium plus olanzapine or valproate semisodium plus risperidone for 28 days. Improvements from baseline were observed in all treatment groups, with statistically significant treatment differences favoring combination treatments on the Positive and Negative Syndrome Scale (PANSS) total score by day 3 and persisting to day 21 ( p < 0.05), but not to day 28 ( p ¼ 0.108). An 84-day study failed to replicate the apparent early robust response to adjunct valproate (http://www.clinicalstudyresults.org/documents/companystudy_782_0.pdf.) Similarly, a Cochrane Database review (Basan et al., 2004 ) that examined the effectiveness of valproate as an adjunct to antipsychotic medications in mixed age schizophrenia populations noted no significant effect of using valproate as an adjunct to antipsychotic therapy. Randomized, controlled trials with valproate semisodium have also been conducted to evaluate effects on behavioral symptoms in elderly dementia populations (Porsteinsson et al., 2001; Sival et al., 2002; Tariot et al., 2005) . However, the findings are consistent with the relatively unpromising results across varying psychotropic compounds for symptoms of dementia (Sink et al., 2005) .
In spite of the inconsistent/negative randomized, controlled trials (RCTs) in general schizophrenia populations, it has been suggested that valproate may remain a useful adjunct in sub-populations with schizophrenia who are sub-optimally responsive to antipsychotic monotherapy or who have other atypical presentations such as prominent mood or anxiety symptoms or those with aggressive behavior (Basan et al., 2004; Stahl, 2004; Townsend and Wilson, 2005; Gobbi et al., 2006) . Elderly individuals, who may be unusually sensitive to adverse effects of antipsychotics, or those older adults who have remaining symptoms even with antipsychotic medication treatments may potentially benefit from adjunctive valproate.
Individuals in the study reported here received relatively modest doses of valproate semisodium (mean dose 587.5 mg/day), considerably lower than the doses reported in the study by Casey and colleagues (2003). In the mixed age trial conducted by Casey and colleagues (2003), 29% of individuals experienced somnolence, which was the most common reported side effect of all treatments. Consistent with the report by Basan and colleagues (2004) , sedation was the most common adverse effect (30% of individuals) among older adults in this study who received adjunct valproate semisodium. In some instances, dosing increases in our older adults sample were limited by subjective experience of sedation or tiredness.
The mechanism of action by which adjunct anticonvulsant medications may be helpful in refractory or resistant psychosis is unclear. It has been suggested that diminished prefrontal cortical dopamine activity may contribute to impaired cognition among individuals with schizophrenia, and that use of adjunct anticonvulsant therapy may enhance release of cortical dopamine. Ichikawa and colleagues (2005) recently reported that valproate, when combined with antipsychotics, produces greater increases in prefrontal cortical dopamine release than either type of drug alone via a mechanism dependent upon 5HT (1A) receptor activation. Alternatively, colleagues (1999, 2003) have suggested that abnormalities in the gamma-aminobutyric acid (GABA) neurotransmitter system implicated in the pathogenesis of schizophrenia, may be at least partially corrected by GABA-ergic agonists such as valproate.
While the MMSE did not demonstrate change with valproate semisodium therapy in this non-demented population, it is possible that more subtle improvements in cognition could have been at least in part demonstrated by changes seen on the other psychopathology ratings such as the PANSS. It is known that valproate co-administration can increase plasma concentrations and area under the plasma concentration-time curve (AUC) of the anticonvulsants lamotrigine and carbamazepine, lorazepam and some antidepressants (Calvo et al., 1986; Anderson, 1998; Fuller, 2007) . Adjunctive valproate therapy has been reported to have minimal effects on steady state serum levels of some antipsychotic compounds (Citrome et al., 2005; Fuller, 2007) .
In this study, older adults were initially begun on valproate semisodium delayed release (DR) and then transitioned to valproate semisodium extendedrelease (ER). Citrome and colleagues (2004) reported on the safety, efficacy and tolerability of switching from valproate semisodium DR formulation to once-daily dosing with valproate semisodium ER in 30 individuals with schizophrenia. Patients were converted from valproate semisodium DR to ER formulation on a 1.0:1.0 basis (rounded up to the nearest 500-mg increment) for initial plasma valproate levels !85 mg/mL and on a 1.0: 1.2 basis for initial plasma levels of <85 g/mL . Baseline and endpoint changes on psychopathology and adverse event ratings scales (Positive and Negative Syndrome (PANSS) and Udvalg for Klinishke Undersogelser Side Effect Rating Scale (UKU)) were minimally changed and baseline and end-point serum trough valproate semisodium levels were 80.1 and 73.1 respectively, suggesting that switch-over was well tolerated and that the differences in serum levels were of small magnitude.
Consistent with the procedures of the small trial reported here, it appears that individuals receiving valproate semisodium DR can be readily converted to valproate semisodium ER on a 1:1, or perhaps a 1.0:1.2 basis. In the case of older adults with schizophrenia, the once-daily dosing formulation was more easily remembered and accommodated into an individual's life-style than multiple-dosed valproate semisodium.
The findings of this study must be interpreted cautiously given the limitations of small sample size, open-label, add-on design and lack of a control or comparator group. Additionally, the sample mean age of approximately 61 years is not representative of the 'old-old' populations seen in some geriatric-focused studies, and results cannot necessarily be extrapolated to the oldest geriatric populations with schizophrenia.
In conclusion, this uncontrolled prospective study of adjunctive valproate semisodium in older adults with schizophrenia suggests that the addition of valproate semisodium to antipyschotic treatment may be associated with improvement in symptoms. Larger, controlled studies are needed to further evaluate the effects of adjunctive valproate semisodium on symptoms of schizophrenia in older adult populations.
